Skip to main content
Download PDF
  • Primary research
  • Open access
  • Published:

LINC00221 silencing prevents the progression of hepatocellular carcinoma through let-7a-5p-targeted inhibition of MMP11

Cancer Cell International volume 21, Article number: 202 (2021) Cite this article

Abstract

Background

Microarray profiles of hepatocellular carcinoma (HCC) identified that long intergenic noncoding RNA 00221 (LINC00221) was upregulated. Herein, we aimed to identify the functional significance and underlying mechanisms of LINC00221 in HCC.

Methods and results

Human HCC samples had increased expression of LINC00221. Effects of LINC00221 on HCC cellular functions were analyzed using gain- and loss-function approaches. LINC00221 knockdown repressed HCC cell growth, migration, and invasion and enhanced their apoptosis. This anti-tumor effect was validated in vivo. Online prediction showed the potential binding relationship between LINC00221 and let-7a-5p, as well as that between let-7a-5p and matrix metalloproteinase 11 (MMP11). The results of luciferase, RNA immunoprecipitation, and RNA pull-down assays identified that LINC00221 interacted with let-7a-5p to increase expression of MMP11. Furthermore, we demonstrated that LINC00221 silencing increased let-7a-5p and inhibited MMP11 expression, thereby delaying the progression of HCC in vitro.

Conclusions

Silencing of LINC00221 could prevent HCC progression via upregulating let-7a-5p and downregulating MMP11. As such, LINC00221 inhibition presents a promising antitumor strategy for the treatment of HCC.

Background

Hepatocellular carcinoma (HCC) is the predominant histological subtype among primary liver cancers, and ranks 2nd among cancer-related deaths in China [1, 2]. HCC usually occurs in a condition of chronic inflammation [3]. Most cases of HCC arise in developing countries, but the global incidence is increasing in parallel with its risk factors, namely obesity, alcoholism, as well as hepatitis C [4]. The prospects for long-term survival with HCC remains poor [5], since most available treatment protocols do little to alter the poor prognosis, and only one third of cases are eligible for curative treatments [6]. Therefore, there is an urgent need to obtain a better understanding of the genetic and physiological factors that mediate the progression of HCC.

Multiple long non-coding RNAs (lncRNAs) possess the vital potential to control cellular process involved in the pathophysiology of HCC [7]. LncRNAs are a group of non-protein-coding transcripts with a length of 200 or more nucleotides; dysregulation of lncRNAs possibly contributes to development and progression of tumors [8]. Long intergenic noncoding RNA 00,221 (LINC00221), also known as NCRNA00221 [9], is an lncRNA recognized to be a potential prognostic biomarker for HCC [10]. However, its involvement in HCC progression remains to be established. LncRNAs have been widely identified to function as competitive endogenous RNAs (ceRNAs) or sponges of microRNAs (miRNAs), thus mediating effects on the post-transcription regulation of mRNAs [11]. For example, a previous study has suggested that the lncRNA Ras suppressor protein 1 pseudogene 2 (RSU1P2) mediates gene expression in cervical cancer by functioning as a ceRNA of let-7a [12]. Importantly, miRNA let-7a exhibits low expression levels in HCC cells [13]. Other studies show that silencing of lncRNA LINC01561 can suppress proliferation while enhancing the apoptosis of BrCa cells by increasing miR-145-5p and decreasing matrix metalloproteinase 11 (MMP11) expression [14]. MMP11 acts as a regulator of HCC proliferation and metastasis [15]. The results from the RNA22, Starbase, mirDIP, and miRDB databases, predicted that LINC00221 could bind to let-7a-5p, which in turn could bind to MMP11. Therefore, we hypothesized that LINC00221 might have a crucial modulatory effect on the growth of HCC cells through the let-7a-5p/MMP11 axis.

Methods

Microarray-based RNA expression profiling

We downloaded microarray profiles and annotation probe files related to HCC from the Gene Expression Omnibus (GEO) database (Table 1). The Affy package of R software was employed to perform background correction and normalization processing for the microarray data [16]. Using |log2 (fold change)|> 1 and value < 0.05 as threshold criteria, the Limma package (http://master.bioconductor.org/packages/release/bioc/html/limma.html) was applied to screen out the differentially expressed lncRNAs/miRNAs/mRNAs. HCC-related lncRNAs were screened from the GSE33006 microarray, which contained data from three pairs of HCC tissue samples and adjacent normal liver tissues. The downstream regulatory miRNAs of candidate lncRNA were predicted using the RNA22 database, which were intersected with the down-regulated miRNAs in HCC screened from GSE12717 to select candidate miRNAs. The target genes of candidate miRNAs were obtained from the Starbase, mirDIP, and miRDB databases, and then were intersected with up-regulated genes in HCC from the GSE89377 and GSE117361 microarrays using the Venn website. Data of HCC prognosis and HCC-related gene expression from The Cancer Genome Atlas (TCGA) database were further analyzed using R software. The package edgeR of R software was applied for differential analyses of the transcriptome profiling data [17], and false positive discovery (FDR) correction was utilized with the p-value defined by the package multi-test. The differentially expressed genes (DEGs) were screen out with the threshold of FDR < 0.05 and |log2 (fold change)|> 2.

Table 1 HCC-related microarray profiles
Full size table

Study subjects

The HCC tissues as well as the adjacent non-tumor tissue (adjacent to the tumor margin at a distance greater than 2 cm) were collected from 45 HCC patients and subsequently stored in liquid nitrogen. The enrolled patients included 26 males and 19 females (aged 32–69 years), with 17 cases having a tumor size ≤ 5 cm and the remaining 28 cases with tumor size > 5 cm; 15 cases had multiple tumors and 30 cases had a single tumor. The clinical stage of all patients was determined based on the Edmondson-Steiner grade [18], with 21 cases regarded as grade I/II and 24 cases as grade III. Based on the Tumor-Node-Metastasis (TNM) staging classification of Modified Union for International Cancer Control (mUICC) stage [19], 28 cases were confirmed to be stage I/II and 17 cases as stage IIIa. The inclusion criteria were based on the following clinical manifestations: (1) alpha-fetoprotein (AFP) level maintained ≥ 200 µg/mL for one month; (2) AFP level maintained ≤ 200 µg/mL for two months [20]; (3) The diagnosis of HCC was confirmed by means of abdominal CT scans on a Philips Brilliance CT 64-channel scanner (Philips Medical Systems, Eindhoven, the Netherlands) [21]. The exclusion criteria were as follows: patients who had a history of chemotherapy or radiotherapy, or who had participated in other clinical trials (including placebo-controlled trials) within three months before the experiment, had received immunotherapy, or suffered from hepatitis B virus (HBV) or primary biliary cirrhosis [22].

Fluorescence in situ hybridization (FISH) assay

A FISH assay was conducted to identify the subcellular localization of LINC00221 in the HCC cells [23]. HCC cells were seeded in a 24-well plate at a concentration of 5 × 103 cells per well. After 24 h, the supernatant was removed, and the cells were fixed with 4% paraformaldehyde, permeated in 0.1% Triton X-100, and then treated with pre-hybridization solution at 37 °C. The double-stranded DNA probe was incubated in a water bath at 75 °C for 5 min and then immediately placed on ice for denaturation. 5–10 min later, the prepared chromosome slide specimen was denatured, and 10 µL denatured or pre-annealed biotin-labelled LINC00221 probe (Shanghai Gefan Biotechnology Co., Ltd., Shanghai, China) was dropped on the denatured and dehydrated slide specimen. The specimen was then covered with an 18 × 18 coverslip, sealed with parafilm, and was placed in a humidified cassette at 37 °C to hybridize overnight (approximately 15–17 h). The next day, elution was then carried out to remove non-specifically bound probes, followed by hybridization signal amplification. Ten minutes later, samples were analyzed under an Axio Observer A1 inverted microscope (Carl Zeiss, Jena, Germany).

Cell transfection

The human normal liver cell line (HL-7702) and three HCC cell lines (MHCC97-H, Huh7, and Hep3B) obtained from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China) were employed for this study. The cells were incubated with Dulbecco's modified Eagle’s medium supplemented with 20% fetal bovine serum, penicillin (50 U/mL) and streptomycin (50 U/mL) at 37 °C with 5% CO2, followed by sub-culture until the cells attained a logarithmic growth rate. HL-7702, MHCC97-H, Huh7, and Hep3B cells were incubated in a 6-well plate until attaining 80% confluence. The cells at passage three were utilized for cell line selection. Expression patterns of LINC00221 were determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Next, the cell lines MHCC97-H and Huh7 with high LINC00221 expression were assigned into blank (cells without transfection), si-LINC00221 (cells transfected with siRNA against LINC00221), and si-negative control (NC) groups (cells transfected with scramble siRNA). Lipofectamine 2000 (Invitrogen Inc., Carlsbad, CA) was employed for cell transfection.

According to the sequence information for LINC00221 (NR_122034.1) in the Genebank, we designed three LINC00221 sequences. After successful construction of the recombinant plasmid and verification by sequencing, the plasmid was extracted, and the cell concentration determined prior to preservation at − 20 °C for later use. Cells (5 × 103 cells/well) were allowed to incubate in a 6-well plate for 24 h and subsequently transfected using Lipofectamine 2000. After a 48-h transfection period, transfection efficiency was visualized under a microscope (CFM-500E/CFM-500Z, Changfang Optical Instruments Co., Ltd., Shanghai, China).

RT-qPCR

Total RNA was extracted using an RNA extraction kit (Takara Biotechnology Ltd., Dalian, China) based on the Trizol method. The absorbance (A) at 260 nm and 280 nm was measured with a spectrophotometer (PHLES, China). The high quality of the RNA was confirmed by an A260/A280 ratio in the range 1.9–2.0. The RNA reverse transcription was conducted with the application of TaqMan microRNA assay RT primer (4427975, Applied Biosystems, Foster City, CA) and Primescript RT reagent kits (rr047a, Takara, Tokyo, Japan). The primers were designed and synthesized by Takara (Table 2). GAPDH was used as internal reference for LINC00221, while U6 was used for let-7a-5p. PCR was conducted on an ABI7500 quantitative PCR instrument (Applied Biosystems). The reaction conditions consisted of pre-denaturation at 95 °C for 10 min, 40 cycles of 10 s denaturation at 95 °C, 20 s annealing at 60 °C, and 34 s extension at 72 °C. The 2−ΔΔCt method was applied to determine the relative expression of the target. ΔΔCt = ΔCt (experimental group) − ΔCt (control group); ΔCt = Ct (target gene) − Ct (internal control).

Table 2 Primer sequences for RT-qPCR
Full size table

Western blot analysis

The total protein extraction from tissues or cells was conducted with radioimmunoprecipitation assay (RIPA) lysis buffer (P0013c, Beyotime Biotechnology, Shanghai, China) containing phenyhnethylsulfonyl fluoride (PMSF). The supernatant was incubated on ice for 30 min, and centrifuged at 4 °C and 8000 g for 10 min, followed by bicinchoninic acid (BCA) protein assay (CWBio, Beijing, China). The extracted proteins were stored at – 80 ℃ after packaging. The proteins were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) for 1 h, transferred onto nitrocellulose membranes, and then blocked with 5% skimmed milk (PBS) for 2 h. The membranes were incubated for 30 min at ambient temperature with rabbit polyclonal antibodies MMP11 (1:1000, ab119284), Bcl-2 (1:1000, ab182858), Cyclin D1 (1:1000, ab40754), CDK4 (1:1000, ab199728), Bax (1:1000, ab182733), and GAPDH (ab9485, 1:2500) (Abcam, Cambridge, UK). HRP-coupled antibody to immunoglobulin G (IgG) (A21020, 1:5000, AmyJet Scientific Inc., Wuhan, China) was loaded for 1-h incubation. The immunoblots were subsequently developed using enhanced chemiluminescence reagent (BB-3501, Amersham Biosciences, Piscataway, NJ), and imaged on the gel imager. An imaging system (Bio-Rad Inc., Hercules, CA) was utilized for gray value analysis with the application of Quantity One v4.6.2 software [24].

3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide (MTT) assay

After the transfection process, the cells were trypsinized. The cell suspension (5 × 103 cells/well) in a 96-well plate was added with 20 μL MTT solution (GD-Y1317, Guduo Biotechnology Company, Shanghai, China) per well at 24, 48 and 72 h post transfection, respectively. The supernatant was aspirated after centrifugation, followed by the addition of 150 μL dimethylsulfoxide (DMSO; D5879-100ML, Sigma-Aldrich, SF, CA) into each well. The optical density (OD) value was measured at 490 nm using a microplate reader (DG5031, Shanghai Bajiu Industrial Co., Ltd., Shanghai, China) [25]. Cell viability = (OD valueexperimental group − ODblank group) / (ODcontrol group − ODblank group) × 100%.

Flow cytometry

After transfection for 48 h, the cells were fixed, centrifuged, and dyed with 500 μL solution containing propidium iodide (PI, 50 μg/mL) (88378, Sigma-Aldrich) and RNase A (100 μg/mL) (GE101-01, TransGen Biotech Co., Ltd., Beijing, China). A CytoFLEX flow cytometer (excitation wavelength: 488 nm) was utilized to analyze the cell cycle.

Forty-eight h post transfection, the prepared Annexin-V/PI dying solution with Annexin-V-fluorescein isothiocyanate (FITC), propidium iodide (PI) and N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES) buffer (1:2:50) were incubated with cells together for 10 min. The cells were probed with fluorescent solution SA-FLOUS (Origin Biosciences Inc., Nanjing, China) after centrifugation. To assess cell apoptosis, the fluorescence was detected using a 620-nm bandpass filter for PI and a 525-nm bandpass filter for FITC at 488-nm excitation wavelength, respectively [26].

Scratch test

Uniform horizontal lines were drawn on the surface of the 6-well plates. Scratches perpendicular to the horizontal lines were subsequently made on the cell monolayers. Images were obtained at 0 and 24 h of incubation using an inverted microscope, and the cell migration distance between the scratches was measured accordingly [27].

Transwell assay

Transwell assay was conducted in a Transwell chamber by conventional means, with staining with crystal violet for 20 min, whereupon the cells that had migrated through the Matrigel were counted in three randomly selecting fields from each sample [28].

RNA immunoprecipitation (RIP)

The binding between LINC00221 and Argonaute 2 (Ago2) protein as well as that between let-7a-5p and Ago2 was assessed using a RIP kit (Millipore Company, Billerica, MA). The cells were lysed by incubation in RIPA lysis buffer (P0013B, Beyotime Biotechnology) in an ice bath, followed by 10-min centrifugation at 14,000 rpm at 4 ℃. For each coprecipitation reaction system, 50 μL magnetic beads were resuspended with 100 μL RIP wash buffer, with addition of 5 μg antibody: rabbit anti-Ago2 (1:100, ab32381, Abcam) or rabbit anti-human IgG (1:100, ab109489, Abcam) (used as NC). The obtained bead-antibody complex was then incubated overnight at 4 °C with cell lysate (100 μL). One portion of the cell lysate was employed as the input. The samples and input were detached by protease K to extract RNA, followed by RT-qPCR.

RNA pull-down

Transfection was performed with the wild type (WT)-biotinylated LINC00221 and mutant type (MUT)-biotinylated LINC00221 (50 nM for each) for 48 h. Next, the cell lysate was reacted at 4 °C with M-280 streptavidin magnetic beads (Sigma-Aldrich) that was precoated with RNase-free yeast tRNA (Sigma-Aldrich). 3 h later, the beads were rinsed. Finally, the expression of let-7a-5p in the eluted RNA was determined by RT-qPCR.

Dual-luciferase reporter assay

The cells (2 × 105 cells/well) in 6-well plates were transfected, and cultured for 48 h. The luciferase activities of LINC00221 and MMP11 in the cells were determined through application of the Genecopoeia dual-luciferase detection kit (D0010, Solarbio, Beijing, China). The luminance was detected using the Glomax20/20 luminometer provided by Promega (E5311, Zhongmei Biotechnology Co., Ltd., Shanxi, China).

Animal treatment

Forty-eight healthy nude mice (aged 6–8 weeks, weighing about 18–22 g) were purchased from the Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences (Beijing, China). Mice were separately caged for 7 days in a specific-pathogen-free animal laboratory with 60–65% humidity, 22–25 °C, and free access to feed and water, under a 12 h light/dark cycle. Mice were subcutaneously inoculated with 1 × 106 cells/µL of cell suspension. Specifically, Huh7 and MHCC97-H cells (2 × 105 cells/well) were seeded into a 6-well cell culture plate. Upon attaining 30% confluence, cells were infected with lentivirus (2 × 106 TU) expressing short hairpin RNA (sh)-NC, sh-LINC0022, oe-NC, or oe-LINC0022. The lentivirus was mixed with 5 μg poly-brene, which was added into 1 mL serum-free and anti-bacterial medium. The infection efficiency was monitored under an inverted fluorescence microscope for 2–3 days. After 48 h of infection, puromycin (1 μg/mL) was added into each well to select stably infected cells. The cells were further cultured with complete medium after obtaining the stably infected cells. The tumor volume of each mouse was measured every seven days for five weeks, whereupon the mice were euthanized, and the tumor was removed and weighted.

Statistical analysis

SPSS 21.0 software (IBM Corp., Armonk, NY) was utilized for data analysis (p < 0.05 was defined as statistically significant). Measurement data were expressed as mean ± standard deviation. All experiments were independently conducted three times, and all data were evaluated for normality and homogeneity of variance. Comparison between cancerous and adjacent non-cancerous tissues was made using paired t-test while that between other two groups was performed by unpaired t-test. Multiple groups were compared by one-way analysis of variance (ANOVA) with Tukey’s post hoc test. The repeated measures ANOVA was performed for the comparison of tumor volume at different time points, whereas two-way ANOVA was conducted for comparing cell viability at indicated time points, followed by Bonferroni post hoc test.

Results

LINC00221 is highly expressed in HCC

Microarray analysis (GSE33006) revealed an upregulation of LINC00221 in HCC (Fig. 1a–c). Analysis by RT-qPCR demonstrated noticeably higher expression of LINC00221 in the HCC tissues versus adjacent non-tumor tissues (Fig. 1d). LINC00221 expression in three HCC cell lines (MHCC97-H, Huh7, and Hep3B) was measured by RT-qPCR. Consistently, higher LINC00221 expression was observed in Huh7 and MHCC97-H cell lines than in HL-7702, so these two cell lines were selected for subsequent cell experiments (Fig. 1e). After cell transfection, si-LINC00221-1, si-LINC00221-2 and si-LINC00221-3 decreased the LINC00221 expression, among which the si-LINC00221-1 treatment exhibited the best silencing efficiency (Fig. 1f). Therefore, the si-LINC00221-1 was selected for the LINC00221 loss-of-function experiments.

Fig. 1
figure 1

LINC00221 is robustly induced in HCC. a heat maps with hierarchical clustering analysis for microarray GSE33006 obtained from GEO database (http://www.ncbi.nlm.nih.gov/geo). The abscissa indicates different individuals, the ordinate on the right indicates the gene; the left dendrogram refers to clustering. The upper figure shows whether the sample type consists of normal or tumor; the histogram in the upper right refers to color gradation, which indicates gene expression. The color refers to the analysis of DEGs expression, with each square representing the expression of one gene in one sample. b Circos map of microarray GSE33006. c LINC00221 expression in HCC from TCGA database (http://cancergenome.nih.gov/). d LINC00221 expression in the HCC tissues and adjacent non-tumor tissues examined by RT-qPCR (n = 45). e the expression of LINC00221 in 3 MHCC97-H, Huh7 and Hep3B cell lines determined by RT-qPCR. f Silencing efficiency of LINC00221 examined by RT-qPCR. Cell experiments were independently repeated 3 times. *p < 0.05; **p < 0.05. Comparison between two groups was made by paired t-test while comparison among multiple groups was made using one-way ANOVA with Tukey’s post hoc test

Full size image

After correlation analysis, we determined that LINC00221 expression was highly correlated to lymph node metastasis (LNM), clinical grade, TNM staging, and AFP content (Table 3). Patients at stage IIIa HCC exhibited a lower positive expression of LINC00221 (37.78%) than that those at stage I/II HCC (62.22%). The positive expression of LINC00221 in grade I//II patients (46.67%) was lower than that in patients at grade III (53.33%). Positive expression of LINC00221 in patients with LNM (24.44%) was lower than that in patients without LNM (75.56%), while the positive expression of LINC00221 in patients with an AFP greater than 200 ng/mL (53.33%) was higher than those with an AFP less than or equal to 200 ng/mL (46.67%). However, LINC00221 expression displayed no marked difference in terms of gender, age, or tumor volume and number.

Table 3 The correlation of LINC00221 expression with the progression of HCC
Full size table

Repression of LINC00221 inhibits proliferation and enhances apoptosis of HCC Cells

As depicted in Fig. 2a, the results of the MTT assay revealed no significant difference at the 24th h post transfection between the Huh7 and MHCC97-H cells. Cell viability was notably lowered by si-LINC00221 but enhanced by oe-LINC00221 in both cell lines. Additionally, as revealed by the PI single staining results (Fig. 2b, c, Additional file 1: Figure S1A, B), there was no significant difference concerning cell cycle in either cell line among blank, si-NC and oe-NC groups. si-LINC00221 treatment resulted in an elevated proportion of the cells at the G1 phase, but a reduced proportion of the cells at the S phase, while oe-LINC00221 led to enhanced cell cycle entry both in Huh7 and MHCC97-H cells. Annexin V/PI double staining results displayed no significant difference among the blank, si-NC and oe-NC groups in either cell line. However, their apoptosis rates were elevated by si-LINC00221 but reduced by oe-LINC00221 treatment (Fig. 2d, e, Additional file 1: Figure S1C, D). Therefore, silencing LINC00221 could inhibit cancer progression in HCC cells.

Fig. 2
figure 2

Suppression of LINC00221 inhibits cell viability and cell cycle entry while enhancing cell apoptosis in HCC (Huh7 and MHCC97-H) cells. a viability of Huh7 and MHCC97-H cells upon LINC00221 silencing or overexpression assessed by MTT assay. B-C, cell cycle distribution in Huh7 (b) and MHCC97-H (c) cells upon LINC00221 silencing or overexpression examined by flow cytometry. D-E, the apoptosis in Huh7 (d) and MHCC97-H (e) cells after silencing or overexpression of LINC00221 examined by flow cytometry. Cell experiments were independently repeated 3 times. *p < 0.05 vs. the si-NC group; #p < 0.05 vs. the oe-NC group. Comparison among multiple groups was made using one-way ANOVA with Tukey’s post hoc test while data at different time points were compared using two-way ANOVA with Bonferroni post hoc test

Full size image

Repression of LINC00221 reduces the migration and invasion of HCC cells

As revealed by the data from Scratch test and Transwell assay, the Huh7 and MHCC97-H cells exhibited consistent changes following alternations of their LINC00221 expression. As illustrated in Fig. 3a, b, Additional file 2: Figure S2A, B, Fig. 3c, d, and Additional file 2: Figure S2C, D, si-LINC00221 induced significantly decreased cell migration distance and fewer invasive cells, while oe-LINC00221 caused enhanced cell migration and invasion.

Fig. 3
figure 3

Downregulation of LINC00221 restrains migration and invasion of HCC (Huh7 and MHCC97-H) cells. a, b migration distance of Huh7 (a) and MHCC97-H (b) cells assessed by scratch test. c, d number of invaded Huh7 (c) and MHCC97-H (d) cells examined by Transwell assay. e, f Bcl-2, Bax, Cyclin D1, and CDK4 protein expression in Huh7 (e) and MHCC97-H (f) cells measured by Western blot analysis. Cell experiments were independently repeated 3 times. *p < 0.05 vs. the si-NC group; #p < 0.05 vs. the oe-NC group. Comparison among multiple groups was made using one-way ANOVA with Tukey’s post hoc test

Full size image

The expression patterns of anti-apoptotic protein Bcl-2, pro-apoptotic protein Bax, and cell cycle markers cyclin D1 and CDK4 in Huh7 cells and MHCC97-H cells were measured by immunoblotting. The expression of Bcl-2, cyclin D1 and CDK4 was significantly decreased, while that of Bax was increased upon si-LINC00221 treatment. However, the expression of Bcl-2, cyclin D1 and CDK4 was enhanced, while Bax expression was reduced in response to oe-LINC00221 treatment (Fig. 3e, f). Taken together, the above findings led us to conclude that silencing LINC00221 suppressed the migrating and invading properties of HCC cells.

Inhibition of LINC00221 suppresses tumor growth in HCC

We further investigated whether LINC00221 could function in vivo. LINC00221-deficient or LINC00221-overexpressed Huh7/MHCC97-H cells were transplanted into HCC nude mice. The expression of LINC00221 was markedly reduced in the tumor xenografts of nude mice transplanted with LINC00221-deficient Huh7/MHCC97-H cells, while its expression was considerably elevated in the tumor xenografts of mice transplanted with Huh7/MHCC97-H cells overexpressing LINC00221 (Additional file 3: Figure S3). The volume and weight of transplanted tumors were significantly reduced by LINC00221 knockdown, yet the volume and weight of transplanted tumors were notably elevated upon enhanced LINC00221 expression (Fig. 4a–c). These findings suggested that silencing of LINC00221 was capable of suppressing tumor growth in vivo.

Fig. 4
figure 4

Suppression of LINC00221 inhibits tumor growth in vivo. a Tumor volume in nude mice; b Representatives images of transplanted tumors formed in nude mice; c Tumor weight. N = 6. *p < 0.05 vs. the sh-NC group; #p < 0.05 vs. the oe-NC group. Comparison among multiple groups was made using one-way ANOVA with Tukey’s post hoc test while data at different time points were compared using repeated measures ANOVA with Bonferroni post hoc test

Full size image

LINC00221 upregulates the expression of MMP11 by competitively binding to Let-7a-5p

Analysis of an lncRNA subcellular localization website (http://lncatlas.crg.eu/) [29] revealed that LINC00221 was predominately located in the cytoplasm (Fig. 5a). Through the application of FISH, as shown in Fig. 5b, the green-stained LINC00221 probe was mainly located in the cytoplasm, while the nucleus was stained in blue. In merged images, green fluorescence was clearly observed in the cytoplasm, indicative of the localization of LINC00221 in the cytoplasm.

Fig. 5
figure 5

LINC00221 upregulates the MMP11 expression by competitively binding to let-7a-5p. a LncATLAS website for lncRNA subcellular localization revealed that LINC00221 was mainly located in the cytoplasm. b The subcellular localization of LINC00221 verified by FISH assay (× 400; the left) and the co-localization profile intensity (the right). c Venn map (http://bioinformatics.psb.ugent.be/webtools/Venn/) showing downstream regulatory miRNAs of LINC00221 predicted by RNA22 database (https://cm.jefferson.edu/rna22/Precomputed/) (blue circle) and downregulated miRNAs in HCC samples from GSE12717 microarray (red circle). d The binding site between LINC00221 and let-7a-5p sequences predicted on the RNA22 website. e Venn map showing downstream target genes of let-7a-5p predicted by Starbase (http://starbase.sysu.edu.cn/index.php) (blue circle), mirDIP (http://ophid.utoronto.ca/mirDIP/) (red circle), and miRDB (http://www.mirdb.org/) (green circle), and upregulated genes in HCC samples from GSE89377 microarray (yellow circle) and from GSE117361 microarray (orange circle). f The binding site between let-7a-5p and MMP11 predicted on the RNA22 website. g The relationships among LINC00221, let-7a-5p and MMP11 identified by dual-luciferase reporter gene assay. h The let-7a-5p expression in HCC and adjacent non-tumor tissues (n = 45) examined by RT-qPCR. i The MMP11 protein expression in HCC and adjacent non-tumor tissues (n = 45) measured by Western blot analysis. j The relationships among LINC00221, let-7a-5p and Ago2 determined by RIP assay. k The binding of LINC00221 to let-7a-5p identified by RNA pull-down. l The regulatory effect of LINC00221 on let-7a-5p expression examined by RT-qPCR. m MMP11 protein expression after upregulation of let-7a-5p measured by western blot analysis. Cell experiments were independently repeated 3 times. *p < 0.05 vs. the mimic NC group, si-NC group or adjacent non-tumor tissues (n = 45); &p < 0.05 vs. the IgG group; #p < 0.05 vs. the Bio-LINC00221-MUT group. Comparison between HCC and adjacent non-tumor tissues was made using paired t-test while comparison between other two groups was performed by unpaired t-test

Full size image

The downstream regulatory miRNAs predicted by the RNA22 database were intersected with the downregulated miRNAs in HCC samples from the GSE12717 microarray. Only let-7a-5p was present at the intersection (Fig. 5c). We also observed a specific binding site between LINC00221 and let-7a-5p sequences (Fig. 5d). To explore further the downstream mechanism of this interaction, we employed Starbase, mirDIP and miRDB databases to predict the targets of let-7a-5p. By intersecting those target genes with upregulated genes in HCC samples from GSE89377 and GSE117361 microarrays, we identified MMP11, COL1A1 and COL1A2 (Fig. 5e), among which MMP11 has rarely been reported in previous studies on HCC. Moreover, we found a specific binding site between let-7a-5p and the MMP11 sequence (Fig. 5f). The above results suggested that LINC00221 might regulate MMP11 expression via binding to let-7a-5p. To validate this, we then applied a luciferase assay. Results of this assay (Fig. 5e) demonstrated that the luciferase activity of pGL3-LINC00221 or pGL3-MMP11-3′UTR was decreased by co-transfection with let-7a-5p mimic, while that of pGL3-MMP11-3′UTR was also decreased after co-transfection with si-LINC00221. Then, we found that the HCC tissues displayed markedly decreased let-7a-5p expression levels accompanied by elevated MMP11 protein expression relative to adjacent non-tumor tissues (Fig. 5f, g). The application of a RIP assay revealed that, in contrast to the IgG group, the Ago2 group had significantly higher levels of LINC00221 and let-7a-5p expression (Fig. 5h). The application of an RNA pull-down exhibited that, compared with the Bio-LINC00221-MUT group, the Bio-LINC00221-WT group exhibited significantly increased let-7a-5p expression (Fig. 5i). After inhibition of LINC00221, the level of let-7a-5p expression markedly decreased (Fig. 5j), while MMP11 protein expression was conspicuously decreased upon let-7a-5p mimic transfection (p < 0.05) (Fig. 5k). Taken then above, we concluded that LINC00221 upregulated the MMP11 expression by competitively binding to let-7a-5p.

Knock-down of LINC00221 represses the aggressiveness but enhances apoptosis of HCC cells by inhibiting MMP11 via upregulation of Let-7a-5p

Huh7 cells and MHCC97-H cells were transfected with let-7a-5p mimic to explore its effect on the progression of HCC. In particular, we conducted transfection with si-LINC00221 + si-MMP11 or with si-LINC00221 + oe-MMP11 to analyze whether LINC00221 participated in the growth of HCC by regulating the let-7a -5p/MMP11 axis. Results showed that let-7a-5p mimic treatment obviously decreased the MMP11 protein expression. MMP11 protein expression was appreciably lowered by si-MMP11, but rescued by oe-MMP11 treatment in the LINC00221-deficient cells (Fig. 6a). The MTT assay results as displayed in Fig. 6b revealed that cell proliferation was significantly diminished by let-7a-5p mimic, while a similar decrease was induced by si-MMP11 in the LINC00221-deficient cells. However, cell proliferation suppressed by si-LINC00221 was rescued by oe-MMP11. The flow cytometric data in Fig. 6c displayed that let-7a-5p mimic provoked significantly higher cell apoptosis, and that si-MMP11 induced an enhancement of cell apoptosis in LINC00221-deficient cells. On the other hand, cell apoptosis induced by si-LINC00221 was decreased by oe-MMP11. Furthermore, the Transwell assay revealed that cell invasion was markedly decreased by the let-7a-5p mimic treatment, with a similar reduction identified in the LINC00221-deficient cells upon MMP11 knockdown. Moreover, cell invasion suppressed by si-LINC00221 was enhanced by oe-MMP11 (Fig. 6d).

Fig. 6
figure 6

Silencing of LINC00221 inhibits the proliferation and invasion but accelerates apoptosis of HCC (Huh7 and MHCC97-H) cells by upregulating let-7a-5p and suppression of MMP11. The Huh7 and MHCC97-H cells were transfected with let-7a-5p mimic, si-LINC00221 or co-transfected with si-LINC00221 and si-MMP11 or si-LINC00221 and oe-MMP11. a The MMP11 protein expression in Huh7 and MHCC97-H cells examined by Western blot analysis. b The proliferation of Huh7 and MHCC97-H cells assessed by MTT assay. c The apoptosis of Huh7 and MHCC97-H cells examined by flow cytometry. d Number of invaded Huh7 and MHCC97-H cells tested by Transwell assay. e Bcl-2, Bax, cyclin D1, and CDK4 protein expression in Huh7 and MHCC97-H cells measured by Western blot analysis. Cell experiment was independently repeated 3 times. *p < 0.05 vs. the miR-NC group; #p < 0.05 vs. the si-LINC00221 + si-NC group; &p < 0.05 vs. the si-LINC00221 + oe-NC group. Comparison among multiple groups was made using one-way ANOVA with Tukey’s post hoc test while data at different time points were compared using two-way ANOVA with Bonferroni post hoc test

Full size image

At the molecular level, the expression of Bcl-2, Cyclin D1 and CDK4 proteins was decreased, but Bax protein expression was upregulated by let-7a-5p mimic. In contrast to the si-LINC00221 + si-NC group, we observed reduced expression of Bcl-2, cyclin D1 and CDK4 proteins in the si-LINC00221 + si-MMP11 group, accompanied with elevated expression of Bax protein. Conversely, oe-MMP11 could partially reverse the changes in expression of the aforementioned proteins caused by si-LINC00221 (Fig. 6e).

The Huh7 and MHCC97-H cells exhibited similar changes regarding the aforementioned cellular behaviors and molecular levels. Taken together, the results indicated that LINC00221 silencing inhibited MMP11 by upregulating let-7a-5p, thus limiting the malignancy of HCC cells.

Discussion

In the progression of HCC, various genetic and epigenetic alterations regulate the function of proteins post-translationally, which in turn facilitate invasion and metastasis [30]. The present study elucidated the mechanisms associated with the regulatory effects of LINC00221 on HCC cellular behaviors. Our results suggested that LINC00221 promoted the progression of HCC via a mediation of the let-7a-5p/MMP11 axis (Fig. 7).

Fig. 7
figure 7

The mechanism involved LINC00221 in regulating the progression of HCC. LINC00221 was upregulated while let-7a-5p was downregulated in HCC cells, and highly expressed LINC00221 upregulated MMP11 expression by competitively binding to let-7a-5p, thereby promoting HCC cell viability, migration, and restraining cell apoptosis

Full size image

Aberrant expressions of lncRNAs are known for their contribution to hepatocarcinogenesis [31]. Our initial findings in this study revealed that LINC00221 was aberrantly increased in HCC tissues, and that this aberrant increase correlated with advanced LNM, clinical grade and TNM stage of HCC. However, LINC00221 silencing could impede the proliferative, invasive and oncogenic potentials of HCC cells and enhance their apoptosis. It is well-known that lncRNAs can sometimes act as ceRNAs, thus modulating the expression of different miRNAs in a cell-type dependent manner [32]. LINC00221, which is also involved in the ceRNA network in HCC [10], was further observed in this study to act as a ceRNA of let-7a-5p. Existing literature has indicated that let-7a has low expression in HCC cells [33], whereas let-7a overexpression suppresses growth, invasion, and sphere formation capability of HCC stem-like cells [34]. These literature results are partially consistent with our present findings that upregulating let-7a-5p could enhance malignant functions of HCC cells. Similarly, let-7a-5p expression is downregulated in lung cancer, and its decreased expression is conductive to the progression of this cancer [35].

Furthermore, the binding of miRNAs to lncRNAs decreased miRNA levels and led to increased expression of miRNA target genes [36]. The new evidence provided by our study also supported the notion that LINC00221 overexpression resulted in increased MMP11 levels by competitively binding to let-7a-5p. Previous data have suggested that LINC00221 sponges miR-519a to mediate the expression of ZBTB5, which is a mechanism involved in the regulation of cisplatin resistance in non-small-cell lung cancer (NSCLC) [37]. Another let-7 family member, let-7c, targets MMP11 to suppress metastasis in colorectal cancer [38]. Liu et al. have demonstrated that lncRNA nuclear paraspeckle assembly transcript 1 (NEAT1) negatively interacts with let-7a-5p to increase the expression of the let-7a-5p target gene Rsf-1 in NPC [39]. MMP11 has been proposed to be a hub cancer driver gene in lung adenocarcinoma [40]. Our present findings demonstrated that MMP11 exerted tumor-promotive functions on the progression of HCC. Indeed, a large number of previous studies have shown that MMP11 functions as an oncogene in a variety of cancers. For example, inhibition of MMP11 can impede the metastasis of gastric cancer [41]. Likewise, a previous study has shown that knockdown of MMP11 can hamper cancer progression in lung adenocarcinoma cells as well as impeding tumor growth in xenograft models [42]. More importantly, genetic variations in MMP11 may function as a reliable biomarker for the progression of HCC [43], while another study has reported that MMP11 contributes to HCC proliferation and metastasis by acting as the target gene of miR-125a [18]. In this study, we demonstrated that LINC00221 silencing suppressed the in vitro progression of HCC via upregulation of let-7a-5p and inhibition of MMP11 expression. Similarly, suppression of LINC01561 can inhibit cancer cell proliferation and facilitate apoptosis in breast cancer via increasing expression of miR-145-5p as well as reducing expression of MMP11 [17]. Additionally, overexpressing of lncRNA LOXL1-AS1 can accelerate cell proliferating and migrating processes, but restrain apoptosis via upregulating EGFR expression though inhibition of let-7a-5p [44]. Wang et al. have demonstrated that lncRNA antisense non-coding RNA in the INK4 locus (ANRIL) knockdown inhibits the tumorigenicity of NPC cells by modulating let-7a [45].

Conclusion

We have elucidated the potential role of LINC00221 in HCC and provided new evidence that the silencing of LINC00221 contributed to prevention of HCC progression via let-7a-5p-targeted inhibition of MMP11. The demonstration of this mechanistic axis may provide novel insights for developing new targets for the improved treatment of HCC. Present results are encouraging for further investigations with larger sample size and with consideration of the confounding effects of targeted therapy with chemotherapy or chemoresistance on HCC.

Availability of data and material

The datasets generated/analyzed during the current study are available.

Abbreviations

HCC:

Hepatocellular carcinoma

lncRNAs:

Long non-coding RNAs

TCGA:

The Cancer Genome Atlas

GEO:

Gene Expression Omnibus

ceRNA:

Competitive endogenous RNA

miRNAs:

MicroRNAs

RSU1P2:

Ras suppressor protein 1 pseudogene 2

MMP11:

Matrix metalloproteinase 11

FDR:

False positive discovery

DEGs:

Differentially expressed genes

TNM:

Tumor-Node-Metastasis

mUICC:

Modified Union for International Cancer Control

AFP:

Alpha-fetoprotein

FISH:

Fluorescence in situ hybridization

NC:

Negative control

RT-qPCR:

Reverse transcription quantitative polymerase chain reaction

GAPDH:

Glyceraldehyde-3-phosphate dehydrogenase

OD:

Optical density

RIP:

RNA Immunoprecipitation

WT:

Wild type

MUT:

Mutant type

LNM:

Lymph node metastasis

NSCLC:

Non-small-cell lung cancer

NEAT1:

Nuclear paraspeckle assembly transcript 1

References

  1. Zhang Z, Chen C, Guo W, Zheng S, Sun Z, Geng X. DNM3 attenuates hepatocellular carcinoma growth by activating P53. Med Sci Monit. 2016;22:197–205.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Chen YL, Xu QP, Guo F, Guan WH. MicroRNA-302d downregulates TGFBR2 expression and promotes hepatocellular carcinoma growth and invasion. Exp Ther Med. 2017;13(2):681–7.

    Article  CAS  PubMed  Google Scholar 

  3. Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19(3):222–32.

    Article  CAS  PubMed  Google Scholar 

  4. Godoy P, Bolt HM. Hepatocellular cancer. Arch Toxicol. 2013;87(2):225–6.

    Article  CAS  PubMed  Google Scholar 

  5. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, Huang L, Li H, Tan W, Wang C, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 2011;50(2):136–42.

    Article  CAS  PubMed  Google Scholar 

  6. Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, Costentin C, Luciani A, Zafrani ES, Laurent A, Azoulay D, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology. 2016;64(6):2038–46.

    Article  CAS  PubMed  Google Scholar 

  7. Fang TT, Sun XJ, Chen J, Zhao Y, Sun RX, Ren N, Liu BB. Long non-coding RNAs are differentially expressed in hepatocellular carcinoma cell lines with differing metastatic potential. Asian Pac J Cancer Prev. 2014;15(23):10513–24.

    Article  PubMed  Google Scholar 

  8. Yang J, Lin J, Liu T, Chen T, Pan S, Huang W, Li S. Analysis of lncRNA expression profiles in non-small cell lung cancers (NSCLC) and their clinical subtypes. Lung Cancer. 2014;85(2):110–5.

    Article  PubMed  Google Scholar 

  9. Simo-Riudalbas L, Diaz-Lagares A, Gatto S, Gagliardi M, Crujeiras AB, Matarazzo MR, Esteller M, Sandoval J. Genome-wide DNA methylation analysis identifies novel hypomethylated non-pericentromeric genes with potential clinical implications in ICF syndrome. PLoS ONE. 2015;10(7):e0132517.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Long J, Bai Y, Yang X, Lin J, Yang X, Wang D, He L, Zheng Y, Zhao H. Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma. Cancer Cell Int. 2019;19:90.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ye B, Hu B, Zheng Z, Zheng R, Shi Y. The long non-coding RNA AK023948 enhances tumor progression in hepatocellular carcinoma. Exp Ther Med. 2017;14(4):3658–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Mao TL, Fan KF, Liu CL. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer. Gene Ther. 2017;24(10):621–9.

    Article  CAS  PubMed  Google Scholar 

  13. Zhang PF, Li KS, Shen YH, Gao PT, Dong ZR, Cai JB, Zhang C, Huang XY, Tian MX, Hu ZQ, et al. Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling. Cell Death Dis. 2016;7:e2201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Shi DM, Bian XY, Qin CD, Wu WZ. miR-106b-5p promotes stem cell-like properties of hepatocellular carcinoma cells by targeting PTEN via PI3K/Akt pathway. Onco Targets Ther. 2018;11:571–85.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505(7483):344–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Liu Q, Guo X, Que S, Yang X, Fan H, Liu M, Li X, Tang H. LncRNA RSU1P2 contributes to tumorigenesis by acting as a ceRNA against let-7a in cervical cancer cells. Oncotarget. 2017;8(27):43768–81.

    Article  PubMed  Google Scholar 

  17. Jiang R, Zhao C, Gao B, Xu J, Song W, Shi P. Mixomics analysis of breast cancer: Long non-coding RNA linc01561 acts as ceRNA involved in the progression of breast cancer. Int J Biochem Cell Biol. 2018;102:1–9.

    Article  CAS  PubMed  Google Scholar 

  18. Bi Q, Tang S, Xia L, Du R, Fan R, Gao L, Jin J, Liang S, Chen Z, Xu G, et al. Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS ONE. 2012;7(6):e40169.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Fujita A, Sato JR, Rodrigues Lde O, Ferreira CE, Sogayar MC. Evaluating different methods of microarray data normalization. BMC Bioinformatics. 2006;7:469.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.

    Article  PubMed  Google Scholar 

  21. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–40.

    Article  CAS  PubMed  Google Scholar 

  22. Zhou L, Rui JA, Zhou WX, Wang SB, Chen SG, Qu Q. Edmondson-Steiner grade: a crucial predictor of recurrence and survival in hepatocellular carcinoma without microvascular invasio. Pathol Res Pract. 2017;213(7):824–30.

    Article  PubMed  Google Scholar 

  23. Kim TH, Park JW, Kim BH, Kim H, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY, et al. Does risk-adapted proton beam therapy have a role as a complementary or alternative therapeutic option for hepatocellular carcinoma? Cancers. 2019;11(2):230.

    Article  CAS  PubMed Central  Google Scholar 

  24. Lee JC, Cheng CH, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC. Clinical relevance of alpha-fetoprotein in determining resection margin for hepatocellular carcinoma. Medicine. 2019;98(11):e14827.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Jensen NK, Mulder D, Lock M, Fisher B, Zener R, Beech B, Kozak R, Chen J, Lee TY, Wong E. Dynamic contrast enhanced CT aiding gross tumor volume delineation of liver tumors: an interobserver variability study. Radiother Oncol. 2014;111(1):153–7.

    Article  PubMed  Google Scholar 

  26. Montasser MF, Abdelkader NA, Abdelhakam SM, Dabbous H, Montasser IF, Massoud YM, Abdelmoaty W, Saleh SA, Bahaa M, Said H, et al. Bacterial infections post-living-donor liver transplantation in Egyptian hepatitis C virus-cirrhotic patients: a single-center study. World J Hepatol. 2017;9(20):896–904.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Xu JH, Chang WH, Fu HW, Shu WQ, Yuan T, Chen P. Upregulated long non-coding RNA LOC90784 promotes cell proliferation and invasion and is associated with poor clinical features in HCC. Biochem Biophys Res Commun. 2017;490(3):920–6.

    Article  CAS  PubMed  Google Scholar 

  28. Li W, Zhang X, Wang J, Li M, Cao C, Tan J, Ma D, Gao Q. TGFbeta1 in fibroblasts-derived exosomes promotes epithelial-mesenchymal transition of ovarian cancer cells. Oncotarget. 2017;8(56):96035–47.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Liu RT, Cao JL, Yan CQ, Wang Y, An CJ, Lv HT. Effects of LncRNA-HOST2 on cell proliferation, migration, invasion and apoptosis of human hepatocellular carcinoma cell line SMMC-7721. Biosci Rep. 2017;37(2):20160532.

    Article  CAS  Google Scholar 

  30. Zhao S, Chlebowski RT, Anderson GL, Kuller LH, Manson JE, Gass M, Patterson R, Rohan TE, Lane DS, Beresford SA, et al. Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. Breast Cancer Res. 2014;16(2):R30.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Fang Q, Chen X, Zhi X. Long non-coding RNA (LncRNA) urothelial carcinoma associated 1 (UCA1) increases multi-drug resistance of gastric cancer via downregulating miR-27b. Med Sci Monit. 2016;22:3506–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Yoon JH, Abdelmohsen K, Srikantan S, Yang X, Martindale JL, De S, Huarte M, Zhan M, Becker KG, Gorospe M. LincRNA-p21 suppresses target mRNA translation. Mol Cell. 2012;47(4):648–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Zhou T, Gao Y. Increased expression of LncRNA BANCR and its prognostic significance in human hepatocellular carcinoma. World J Surg Oncol. 2016;14(1):8.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Guo C, Song WQ, Sun P, Jin L, Dai HY. LncRNA-GAS5 induces PTEN expression through inhibiting miR-103 in endometrial cancer cells. J Biomed Sci. 2015;22:100.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Zhang L, Hao C, Zhai R, Wang D, Zhang J, Bao L, Li Y, Yao W. Downregulation of exosomal let-7a-5p in dust exposed- workers contributes to lung cancer development. Respir Res. 2018;19(1):235.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Liang WC, Fu WM, Wong CW, Wang Y, Wang WM, Hu GX, Zhang L, Xiao LJ, Wan DC, Zhang JF, et al. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget. 2015;6(26):22513–25.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Wu J, Weng Y, He F, Liang D, Cai L. LncRNA MALAT-1 competitively regulates miR-124 to promote EMT and development of non-small-cell lung cancer. Anticancer Drugs. 2018;29(7):628–36.

    Article  CAS  PubMed  Google Scholar 

  38. Wang X, Lu X, Geng Z, Yang G, Shi Y. LncRNA PTCSC3/miR-574-5p governs cell proliferation and migration of papillary thyroid carcinoma via wnt/beta-catenin signaling. J Cell Biochem. 2017;118(12):4745–52.

    Article  CAS  PubMed  Google Scholar 

  39. Mas-Ponte D, Carlevaro-Fita J, Palumbo E, Hermoso Pulido T, Guigo R, Johnson R. LncATLAS database for subcellular localization of long noncoding RNAs. RNA. 2017;23(7):1080–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Dali-Youcef N, Hnia K, Blaise S, Messaddeq N, Blanc S, Postic C, Valet P, Tomasetto C, Rio MC. Matrix metalloproteinase 11 protects from diabesity and promotes metabolic switch. Sci Rep. 2016;6:25140.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Xu G, Zhang B, Ye J, Cao S, Shi J, Zhao Y, Wang Y, Sang J, Yao Y, Guan W, et al. Exosomal miRNA-139 in cancer-associated fibroblasts inhibits gastric cancer progression by repressing MMP11 expression. Int J Biol Sci. 2019;15(11):2320–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Yang H, Jiang P, Liu D, Wang HQ, Deng Q, Niu X, Lu L, Dai H, Wang H, Yang W. Matrix metalloproteinase 11 is a potential therapeutic target in lung adenocarcinoma. Mol Ther Oncolytics. 2019;14:82–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Wang B, Hsu CJ, Lee HL, Chou CH, Su CM, Yang SF, Tang CH. Impact of matrix metalloproteinase-11 gene polymorphisms upon the development and progression of hepatocellular carcinoma. Int J Med Sci. 2018;15(6):653–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Bai T, Liu Y, Li B. LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells. IUBMB Life. 2019;71(10):1537–51.

    Article  CAS  PubMed  Google Scholar 

  45. Yang X, Xie X, Xiao YF, Xie R, Hu CJ, Tang B, Li BS, Yang SM. The emergence of long non-coding RNAs in the tumorigenesis of hepatocellular carcinoma. Cancer Lett. 2015;360(2):119–24.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We acknowledge and appreciate our colleagues for their valuable efforts and comments on this paper.

Funding

This study was supported by Natural Science Foundation Youth Project of Shaanxi Province (No. 2018JQ8014); Subject Innovation Team of Shaanxi University of Chinese Medicine (2019-YL06) and National Natural Science Foundation Youth Project of China (No. 81704066).

Author information

Author notes

  1. Lin Yang and Hailong Si contributed equally to this work

Authors and Affiliations

  1. Department of Hepatobiliary Surgery, Shaanxi Province, Xianyang Central Hospital, No. 78, Renmin East Road, Weicheng District, Xianyang, 712000, People’s Republic of China

    Lin Yang, Jintao Wang & Cheng Zhang

  2. Department of Oncology, Shaanxi Province, Affiliated Hospital of the Shaanxi University of Traditional Chinese Medicine, No. 2, Weiyang West Road, Xianyang, 712000, People’s Republic of China

    Hailong Si, Meng Ma & Haijuan Xiao

  3. Diagnostic Teaching and Research Unit, Shaanxi University of Traditional Chinese Medicine, Xianyang, 712046, People’s Republic of China

    Yu Fang & Yina Jiang

Authors
  1. Lin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hailong Si
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Meng Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yina Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jintao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Cheng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Haijuan Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LY, HLS, MM, YF and YNJ wrote the paper and conceived and designed the experiments; LY, HLS, MM, YF, JTW, HJX and CZ analyzed the data; JTW, CZ and HJX collected and provided the sample for this study. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Cheng Zhang or Haijuan Xiao.

Ethics declarations

Ethics approval and consent to participate

Written informed consents were signed by all participating patients. The experiments for human tissue samples were approved by Ethic Committee of Affiliated Hospital of the Shaanxi University of Traditional Chinese Medicine and performed in line with the Declaration of Helsinki. The experiments involved animals were conducted in compliance with the Guide for for the Care and Use of Laboratory Animals issued by National Institute of Health. Great efforts were made to minimize the number and suffering of animals.

Consent for publication

Consent for publication was obtained from the participants.

Competing interests

The authors have declared that no competing interests exist.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Figure S1.

Suppression of LINC00221 inhibits cell cycle entry while enhancing cell apoptosis in Huh7 and MHCC97-H cells. A-B, Representative images showing cell cycle in Huh7 (A) and MHCC97-H (B) cells upon LINC00221 silencing or overexpression examined by flow cytometry. C-D, Representative flow cytometric dot plots apoptosis in Huh7 (C) and MHCC97-H (D) cells after silencing or overexpression of LINC00221.

Additional file 2: Figure S2.

Downregulation of LINC00221 restrains migration and invasion of HCC (Huh7 and MHCC97-H) cells. A-B, Representative images of migration distance of Huh7 (A) and MHCC97-H (B) cells assessed by scratch test. C-D, Representative images of invaded Huh7 (C) and MHCC97-H (D) cells examined by Transwell assay.

Additional file 3: Figure S3.

Expression of LINC00221 in the tumor xenografts of nude mice transplanted with Huh7/MHCC97-H cells.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, L., Si, H., Ma, M. et al. LINC00221 silencing prevents the progression of hepatocellular carcinoma through let-7a-5p-targeted inhibition of MMP11. Cancer Cell Int 21, 202 (2021). https://doi.org/10.1186/s12935-021-01819-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12935-021-01819-w

Keywords

Cancer Cell International

ISSN: 1475-2867

Contact us